Income Statement
MOONLAKE IMMUNOTHERAPEUTICS
MLTX
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY |
|---|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - | - |
|
Operating Expenses
|
244.83 | 143.09 | 54.12 | 65.06 | 4.57 | 0.00 |
|
Research & Development
|
202.86 | 112.77 | 31.80 | 42.05 | - | - |
|
Selling, General & Administrative
|
41.97 | 30.32 | 22.32 | 23.01 | 4.57 | - |
|
Other Operating Expenses
|
- | - | - | - | - | - |
|
Operating Income
|
-244.83 | -143.09 | -54.12 | -65.06 | -4.57 | - |
|
Non-Operating Income
|
- | - | - | - | 0.03 | - |
|
Interest Income
|
- | - | - | - | 0.03 | - |
|
Interest Expense
|
7.20 | - | - | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | - | 0.59 | - | - |
|
Income Before Tax
|
-229.71 | -120.96 | -43.98 | -64.47 | - | - |
|
Income Tax Expense
|
0.61 | 0.28 | 0.09 | 0.04 | - | - |
|
Non-Controlling Interest
|
-3.00 | -2.31 | -8.07 | -14.53 | -4.54 | - |
|
Net Income
|
-227.32 | -118.94 | -36.01 | -49.97 | -4.54 | - |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY |
|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - |
|
EBITDA
|
-242.22 | -141.69 | -54.12 | -65.06 | -4.57 | 0.00 |
|
Earnings Per Share (Basic)
|
-3.53 | -1.89 | -0.73 | 0.00 | - | - |
|
Diluted EPS
|
-3.53 | -1.89 | -0.73 | 0.00 | - | - |
|
Weighted Average Shares
|
64.46 | 62.87 | 57.68 | 40.55 | - | - |
|
Diluted Weighted Avg Shares
|
64.46 | 62.87 | 57.68 | 40.55 | 360.00 | - |
|
Comprehensive Income
|
-231.73 | -116.38 | -34.51 | -49.44 | - | - |